BioCardia, Inc. Announces Late-Breaking Echocardiography Results from Phase III CardiAMP HF Trial

BioCardia, Inc. (NASDAQ: BCDA) has issued a significant update for shareholders and the investment community. The company reported late-breaking echocardiography results from its pivotal Phase III clinical trial, the CardiAMP Heart Failure (HF) Trial, targeting ischemic heart failure with reduced ejection fraction (HFrEF). These results were presented by Dr. Amish Raval, M.D., Professor of Medicine at the University of Wisconsin School of Medicine and Public Health and National Co-Principal Investigator of the CardiAMP HF Trial, during a late-breaking clinical trial session at the Technology and Heart Failure Therapeutics (THT) conference.

Key Points for Investors

• Encouraging Echocardiography Outcomes: The press release highlights that patients treated in the CardiAMP HF Trial experienced reduced negative remodeling of heart volumes. This suggests potential benefits in slowing or reversing the structural changes in the heart associated with heart failure, which is a critical measure of disease progression and patient prognosis.
• Phase III Clinical Trial Status: The CardiAMP HF Trial is a late-stage, randomized, controlled study evaluating BioCardia’s autologous cell therapy approach for patients suffering from ischemic HFrEF—a patient population with high unmet medical need and limited options.
• Data Presented at Major Conference: The results were presented in a high-profile, late-breaking session at THT, underscoring their potential impact and relevance to the medical and investment communities.

Potential Price-Sensitive Information and Shareholder Implications

• Potential Market Moving Event: Positive late-stage clinical trial results can be highly price-sensitive for biotech companies. The announcement of reduced negative heart remodeling in treated patients may signal efficacy for the CardiAMP therapy, potentially improving prospects for regulatory approval and future commercialization.
• Upcoming Catalysts: Investors should monitor for additional data releases, regulatory updates, and potential partnerships or licensing opportunities that could follow these results, as these could further impact BioCardia’s valuation.
• Non-Filing Disclosure: The company clarified that the information furnished under Item 7.01 (Regulation FD Disclosure), including the press release, is not deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934. This means it is intended as an informational update and may not have undergone the same level of regulatory scrutiny as formal filings.

Additional Details

• The company’s press release is attached as Exhibit 99.1 to the Form 8-K, providing further insight into the clinical findings and the company’s outlook.
• BioCardia’s common stock trades on the NASDAQ Capital Market under the ticker “BCDA”.
• The company’s headquarters are located at 320 Soquel Way, Sunnyvale, CA 94085.
• For further information, investors and media are directed to contact Miranda Peto (Marketing/Investor Relations) at [email protected] or David McClung (Chief Financial Officer) at [email protected], both at 650-226-0120.

Forward-Looking Statements

The press release includes forward-looking statements regarding the company’s intentions, beliefs, and expectations, which are subject to numerous risks and uncertainties. These include, but are not limited to, uncertainties in product development, regulatory approvals, funding needs, and the ability to enter licensing and partnering arrangements. Actual results may differ materially from those anticipated, and investors are advised to review the company’s filings with the SEC for additional risk factors. BioCardia assumes no obligation to update these statements except as required by law.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. The information herein is based on publicly available documents and may contain forward-looking statements subject to risks and uncertainties. Investors should conduct their own due diligence and consult with financial professionals before making investment decisions. BioCardia, Inc. expressly disclaims any intent or obligation to update the information contained in this article except as required by law.

View BioCardia, Inc. Historical chart here